An ex vivo platform for the prediction of clinical response in multiple myeloma

An ex vivo platform for the prediction of clinical response in multiple myeloma. Silva, A., Silva, M., Sudalagunta, P., Distler, A., Jacobson, T., Collins, A., Nguyen, T., Song, J., Chen, D., Chen, L., Cubitt, ., Baz, R., Perez, L., Rebatchouk, D., Dalton, W., Greene, J., Gatenby, R., Gillies, R., Sontag, E., Meads, M., & Shain, K. Cancer Research, 2017.
abstract bibtex

This paper describes a novel approach for characterization of chemosensitivity and prediction of clinical response in multiple myeloma. It relies upon a patient-specific computational model of clinical response, parameterized by a high-throughput ex vivo assay that quantifies sensitivity of primary MM cells to 31 agents or combinations, in a reconstruction of the tumor microenvironment. The mathematical model, which inherently accounts for intra-tumoral heterogeneity of drug sensitivity, combined with drug- and regimen-specific pharmacokinetics, produces patient-specific predictions of clinical response 5 days post-biopsy.

@ARTICLE{silva2017,
   AUTHOR       = {A. Silva and M. Silva and P. Sudalagunta and A. Distler and 
      T. Jacobson and A. Collins and T. Nguyen and J. Song and D.T. Chen and 
      Lu Chen and . Cubitt and R. Baz and L. Perez and D. Rebatchouk and 
      W. Dalton and J. Greene and R. Gatenby and R. Gillies and E.D. Sontag and 
      M. Meads and K. Shain},
   JOURNAL      = {Cancer Research},
   TITLE        = {An ex vivo platform for the prediction of clinical 
      response in multiple myeloma},
   YEAR         = {2017},
   OPTMONTH     = {},
   OPTNOTE      = {},
   OPTNUMBER    = {},
   PAGES        = {10.1158/0008-5472.CAN-17-0502},
   OPTVOLUME    = {},
   KEYWORDS     = {cancer, multiple myeloma, personalized therapy},
   ABSTRACT     = {This paper describes a novel approach for 
      characterization of chemosensitivity and prediction of clinical 
      response in multiple myeloma. It relies upon a patient-specific 
      computational model of clinical response, parameterized by a 
      high-throughput ex vivo assay that quantifies sensitivity of primary 
      MM cells to 31 agents or combinations, in a reconstruction of the 
      tumor microenvironment. The mathematical model, which inherently 
      accounts for intra-tumoral heterogeneity of drug sensitivity, 
      combined with drug- and regimen-specific pharmacokinetics, produces 
      patient-specific predictions of clinical response 5 days post-biopsy.}
}

Downloads: 0